We are live on ! Find out more
BEAM icon

Beam Therapeutics
BEAM

194 hedge funds and large institutions have $1.62B invested in Beam Therapeutics in 2023 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 79 increasing their positions, 39 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 39

35% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $12.2M

10% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 30

0.9% more ownership

Funds ownership: 84.24% → 85.14% (+0.9%)

0% more funds holding

Funds holding: 194 → 194 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

21% less capital invested

Capital invested by funds: $2.05B → $1.62B (-$428M)

Holders
194
Holders Change
–
Holders Change %
0%
% of All Funds
3.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
33
Increased
79
Reduced
39
Closed
30
Calls
$16.4M
Puts
$12.2M
Net Calls
+$4.21M
Net Calls Change
-$4.96M

Top Buyers

1
FCM
Farallon Capital Management
California
+$27.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$23M
3
State Street
State Street
Massachusetts
+$14.9M
4
WP
Woodline Partners
California
+$12.1M
5
NAMA
Nikko Asset Management Americas
New York
+$11.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$17.2M
2
Morgan Stanley
Morgan Stanley
New York
-$8.39M
3
DTC
Deep Track Capital
Connecticut
-$8.09M
4
HRCM
Hood River Capital Management
Florida
-$8.04M
5
Goldman Sachs
Goldman Sachs
New York
-$7.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
201
TwinBeech Capital
New York
– -$410K -12,846 Closed
CIA
202
Capital Impact Advisors
Massachusetts
– -$402K -12,600 Closed
VIA
203
Vident Investment Advisory
Georgia
– -$358K -11,205 Closed
RMCM
204
Reynders McVeigh Capital Management
Massachusetts
– -$351K -10,996 Closed
CSS
205
Cubist Systematic Strategies
Connecticut
– -$316K -9,909 Closed
SW
206
SteelPeak Wealth
California
– -$299K -9,359 Closed
Two Sigma Advisers
207
Two Sigma Advisers
New York
– -$271K -8,500 Closed
BM
208
Brandywine Managers
Delaware
– -$258K -8,067 Closed
KIA
209
Kraematon Investment Advisors
Massachusetts
– -$253K -7,915 Closed
Two Sigma Investments
210
Two Sigma Investments
New York
– -$236K -7,400 Closed
SEI Investments
211
SEI Investments
Pennsylvania
– -$228K -7,142 Closed
Tudor Investment Corp
212
Tudor Investment Corp
Connecticut
– -$218K -6,821 Closed
Stifel Financial
213
Stifel Financial
Missouri
– -$216K -6,777 Closed
CIC
214
Cornercap Investment Counsel
Georgia
– -$212K -6,655 Closed
Walleye Trading
215
Walleye Trading
New York
– -$164K -6,129 Closed
QT
216
Quantbot Technologies
New York
– -$109K -3,400 Closed
Allspring Global Investments
217
Allspring Global Investments
North Carolina
– -$80K -2,506 Closed
TFM
218
TFC Financial Management
Massachusetts
– -$32.8K -1,027 Closed
RTC
219
Riverview Trust Company
Washington
– -$12.5K -390 Closed
SIC
220
Salem Investment Counselors
North Carolina
– -$1.12K -35 Closed
FGAM
221
Financial Gravity Asset Management
Texas
– -$31 -32 Closed
CA
222
Clearstead Advisors
Ohio
– -$479 -15 Closed
AW
223
Avion Wealth
Texas
– +$590 +22 New
5 6 7 8
9

BEAM Hedge Fund Activity: Q3 2023 in Review

194 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q3 2023, worth a combined $1.62B — down 21% from $2.05B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new BEAM positions and 30 closed out — a net gain of 3 holders — while 79 added to existing stakes and 39 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $27.9M. The largest seller was Fidelity Investments, cutting an estimated $17.2M.

  • 194 institutional investors held Beam Therapeutics (BEAM) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $1.62B of Beam Therapeutics stock for Q3 2023, down 21% quarter-over-quarter.
  • 33 funds opened new Beam Therapeutics positions in Q3 2023 and 30 closed out, a net change of +3 holders.
  • The largest Beam Therapeutics buyer in Q3 2023 was Farallon Capital Management, an estimated $27.9M added.
  • The largest Beam Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $17.2M sold.

Based on aggregated 13F filings for Q3 2023.